$31.92
1.98% yesterday
Nasdaq, Nov 07, 10:08 pm CET
ISIN
US74276L1052
Symbol
PRCT

PROCEPT BioRobotics Stock price

$31.92
-2.69 7.77% 1M
-21.19 39.90% 6M
-48.60 60.36% YTD
-64.31 66.83% 1Y
-7.35 18.72% 3Y
-10.02 23.89% 5Y
-10.02 23.89% 10Y
-10.02 23.89% 20Y
Nasdaq, Closing price Fri, Nov 07 2025
+0.62 1.98%
ISIN
US74276L1052
Symbol
PRCT

New AI Insights on PROCEPT BioRobotics Insights AI Insights on PROCEPT BioRobotics

How does the company make money?
Who are the company’s main competitors?

Key metrics

Basic
Market capitalization
$1.7b
Enterprise Value
$1.5b
Net debt
positive
Cash
$302.7m
Shares outstanding
55.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
6.3 | 5.2
EV/Sales
5.4 | 4.5
EV/FCF
negative
P/B
4.5
Financial Health
Equity Ratio
75.3%
Return on Equity
-22.7%
ROCE
-19.8%
ROIC
-
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$275.0m | $333.1m
EBITDA
$-85.9m | $-40.0m
EBIT
$-91.8m | $-89.4m
Net Income
$-84.2m | $-84.2m
Free Cash Flow
$-89.3m
Growth (TTM | estimate)
Revenue
55.7% | 48.4%
EBITDA
18.0% | 56.2%
EBIT
16.3% | 7.4%
Net Income
18.9% | 7.9%
Free Cash Flow
18.3%
Margin (TTM | estimate)
Gross
64.2%
EBITDA
-31.3% | -12.0%
EBIT
-33.4%
Net
-30.6% | -25.3%
Free Cash Flow
-32.5%
More
EPS
$-1.5
FCF per Share
$-1.6
Short interest
17.4%
Employees
756
Rev per Employee
$300.0k
Show more

Is PROCEPT BioRobotics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.

PROCEPT BioRobotics Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a PROCEPT BioRobotics forecast:

16x Buy
84%
3x Hold
16%

Analyst Opinions

19 Analysts have issued a PROCEPT BioRobotics forecast:

Buy
84%
Hold
16%

Financial data from PROCEPT BioRobotics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
275 275
56% 56%
100%
- Direct Costs 98 98
23% 23%
36%
176 176
83% 83%
64%
- Selling and Administrative Expenses 203 203
35% 35%
74%
- Research and Development Expense 66 66
16% 16%
24%
-86 -86
18% 18%
-31%
- Depreciation and Amortization 5.84 5.84
21% 21%
2%
EBIT (Operating Income) EBIT -92 -92
16% 16%
-33%
Net Profit -84 -84
19% 19%
-31%

In millions USD.

Don't miss a Thing! We will send you all news about PROCEPT BioRobotics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

PROCEPT BioRobotics Stock News

Neutral
Seeking Alpha
3 days ago
PROCEPT BioRobotics Corporation ( PRCT ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Matthew Bacso - Vice President of Investor Relations Larry Wood - President, CEO & Director Kevin Waters - Executive VP & CFO Conference Call Participants Matthew O'Brien - Piper Sandler & Co., Research Division Brandon Vazquez - William Blair & Company L.L.C., Research Division Rich...
Neutral
GlobeNewsWire
3 days ago
SAN JOSE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended September 30, 2025.
Positive
The Motley Fool
10 days ago
Robotics companies building enabling systems like sensors and LiDAR attracted $1.6 billion in 2025, as every robot needs vision capabilities. Medical robotics shows the clearest path from startup to profitability, with surgical automation growing 56% annually in emerging procedures.
More PROCEPT BioRobotics News

Company Profile

PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company, which engages in the development of transformative solutions in urology. It manufactures and sells the AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating BPH. The firm's proprietary AquaBeam Robotic System employs a single-use disposable handpiece to deliver its Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. The company was founded by Nikolai Aljuri and Rodney C. Perkins in 2007 and is headquartered in Redwood City, CA.

Head office United States
CEO Reza Zadno
Employees 756
Founded 2007
Website www.procept-biorobotics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today